Attorney Docket No.: 2543-1-036PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Sonal Patel

SERIAL NO.: 10/509,975 EXAMINER: Unassigned

DATE FILED: October 1, 2004 ART UNIT: Unassigned

FOR: SC6 FOR DIAGNOSIS OF HYPOXIA RELATED CONDITIONS

EXPRESS MAIL NO.: EV 247182638 US

DATE OF DEPOSIT: FEBRUARY 9, 2005

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Attorney Docket No.: 2543-1-036PCT/US

Enclosed please find copies of References **AA** through **CH** listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

DAVID A. JACKSON Attorney for Applicants Registration No. 26,742

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800

- PTO 1110 IDOV - 201	ATTORNEY	Sneet 1 or	
Form PTO-1449 IRSY. 7.801	ATTORNEY DOCKET	2543-1-036PCT/US	
U.S. Department of Commerce Patent and Trademark Office	NO.		
	SERIAL NO.	10/509,975	
LIST OF DOCUMENTARY INFORMATION	APPLICANT	Sonal Patel	
CITED BY APPLICANT (Use several sheets if necessary)	FILING	October 1, 2004	
(coo several effects it hecessary)	DATE		
	GROUP	Unassigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6,225,115	5/1/01	Smith etal.			
	AB	5,658,786	8/19/97	Smith etal.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
ВА	WO 93/18143	9/16/93	PCT		, ,	
вв	EP0631623 - copy not availalbe	1/4/95	Europe			Corresponding Doc- WO 93/18143 attd.
вс	WO 01/ 077389	10/18/01	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Ramamoorthy, S., etal., Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta, 1994, Biochem J., 300 (Pt 3), Pg.893-900.
СВ	Stapleton, PP, etal., Host Defense-A Role for the Amino Acid Taurine?, 1998, J Parenter Enteral Nutr., Jan-Feb, 22(1), Pgs. 42-8.
cc	Schaffer, S, etal., Role of osmoregulation in the actions of taurine, 2000, Amino Acids, 19(3-4), Pgs. 527-46.
CD	Canas, PE, The Role Of Taurine And Its Derivatives On Cellular Hypoxia: A Physiological View, Acta Physiol Pharmacol Ther Latinoam, 42(3), Pgs. 133-7.
CE	Michalk, DV, etal., The Mechanisms Of Taurine Mediated Protection Against Cell Damage Induced by Hypoxia And Reoxygenation, 1996, Adv Exp Med Biol, 403, Pgs. 223-32.
CF	Saransaari, P., etal., Taurine and neural cell damage, 2000, Amino Acids 19 (3-4), Pgs. 509-26.

Sheet	2	of

		311881 2 01
Form PTO:1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY. DOCKET NO.	2543-1-036PCT/US
	SERIAL NO.	10/509,975
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Sonal Patel
	FILING DATE	October 1, 2004
	GROUP	Unassigned

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CG	Niittynen, L, etal., Role of arginine, taurine and homocysteine in cardiovascular diseases, 1999, Ann Med, Oct;31(5), Pgs. 318-26.		
СН	Brown, JM, Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies, 2000, Mol Med Today 6; Pgs. 157-62.		
	·		
XAMINER:	DATE CONSIDERED:		

communication to applicant.